Diversity of senile plaques in Alzheimer's disease as revealed by a new monoclonal antibody that recognizes an internal sequence of the Aβ peptide

Current Alzheimer Research

Volumn 2, Issue 4, 2005, Pages 409-417

  Rábano, Alberto ^a   Jiménez Huete, Adolfo ^b   Acevedo, Boris ^c   Calero, Miguel ^d   Ghiso, Jorge ^e   Valdés, Israel ^d   Gavilondo, Jorge ^d   Frangione, Blas ^e   Méndez, Enrique ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid angiopathy; Amyloid ; Immunohistochemistry; Mass spectrometry; Monoclonal antibody; Neuritic plaques

Indexed keywords

AMYLOID BETA PROTEIN; EPITOPE; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CEREBELLUM CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOUSE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BRAIN CHEMISTRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICE; PEPTIDE FRAGMENTS; SENILE PLAQUES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 24644455547     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720505774330500     Document Type: Article

References (25)

1. Selkoe DJ. Alzheimer's disease: genotypes, phenotype and treatments. Science 275(5300):630-1 (1997).
2. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
3. Vigo-Pelfrey C, Lee D, Keim P, Lieberberg I and Schenk DB. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 61: 1965-1968 (1993).
4. Iwatsubo T, Mann DAM, Odaka A, Suzuki N and Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down's syndrome. Ann Neurol 37: 294-299 (1995).
5. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13: 1-11 (1992).
6. Iwatsubo T, Saido TC, Mann DMA, Lee V M-Y and Trojanowski JQ. Full-lenght amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques. Am J Pathol 149: 1823-1830 (1996).
7. Higgins L, Murphy Jr GM, Forno LS, Catalano R and Cordell B. p3 β-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Path 149: 585-596 (1996).
8. Jimenez-Huete A, Alfonso P, Soto C, Alvar JP, Rábano A, Ghiso J, et al. Antibodies directed to the carboxyl terminus of amyloid β-peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer's disease brain. Alzheimer's Reports 1: 41-48 (1998).
9. Campbell A. Monoclonal antibody technology In: 'Laboratory Techniques in Biochemistry and Molecular Biology' (Eds: Burdon RH, Knippenberg PH) Elsevier, Amsterdam, p. 120-134 (1984).
10. Mirra, SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486 (1991).
11. Iwatsubo T, Mann DAM, Odaka A, Suzuki N and Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down's syndrome. Ann Neurol 37: 294-299 (1995).
12. Fukumoto H, Asami-Okada A, Suzuki N, Shimada H, Ihara Y and Iwatsubo T. Amyloid β protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Am J Pathol 148: 259-265 (1996).
13. Giaccone G, Tagliavini F, Linoli G, Bouras C, Frigerior L, Frangione B, et al. Down syndrome patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 97: 232-238 (1989).
14. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580 (1991).
15. Masliah E, Terry RD, Mallory M, Alford M and Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer Disease. Am J Path 137: 1293-97 (1990).
16. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56: 321-339 (1997).
17. Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica (Berl) 82: 239-259 (1991).
18. Thal DR, Rüb U, Schultz Ch, Sassin I, Ghebremedhin S, Del Tredici K, et al. Sequence of Aβ-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59 (8): 733-748 (2000).
19. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, et al. Chemical characterization of Aβ 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269: 10987-10990 (1994).
20. Kida E, Wisniewski KE and Wisniewski HM. Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of β-peptide in Alzheimer's disease and Down's syndrome brain. Neurosc Lett 193: 105-108 (1995).
21. Lalowski M, Golabek A, Lemere A, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B and Wisniewski T. The "nonamyloidogenic" p3 fragment (amyloid β17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 271: 33623-33631 (1994).
22. Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y and Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE) in senile plaques. Neuron, 14: 457-466 (1995).
23. Tekirian TL, Saido TC, Markesberry WR, Russell MJ, Wekstein DR, Patel E, et al. N-terminal heterogeneity of parenchimal and cerebrovascular Aβ deposits. J Neuropath Exp Neurol 57: 76-94 (1998).
24. Lamer AJ. Hypothesis: amyloid β-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. Neurobiol Aging 20: 65-69 (1999).
25. Parvathy S, Davis P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, et al. Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch Neurol 58: 2025-2032 (2001).